Navigation Links
Lilly Discontinues One of Three Phase 3 Rheumatoid Arthritis Registration Studies for Tabalumab
Date:12/13/2012

INDIANAPOLIS, Dec. 13, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it will stop one of three Phase 3 rheumatoid arthritis (RA) registration studies of tabalumab, an anti-BAFF monoclonal antibody, due to insufficient efficacy. The decision followed a planned interim futility analysis of the FLEX-M study investigating tabalumab, also known as LY2127399, for the treatment of patients with moderate-to-severe RA who had an inadequate response to methotrexate therapy. The decision was not based on safety concerns, and patients currently enrolled in other tabalumab RA studies will continue treatment.

The FLEX-M study was designed to support registration of tabalumab as a potential treatment for RA, including an assessment of its effect on structural progression. Lilly continues to evaluate tabalumab in two other Phase 3 RA registration studies as well as an open-label extension study and several other smaller studies. Lilly is suspending enrollment of new patients in the RA program until additional analysis from other ongoing RA studies is completed in early 2013. These other studies are in different patient populations.

Phase 3 studies for systemic lupus erythematosus are ongoing and will continue to enroll new patients. Currently, there is no evidence to suggest that efficacy results from the FLEX-M study in RA are indicative of potential efficacy in the lupus population. Lilly remains committed to the ongoing Phase 3 lupus program.

"The results of this study were unexpected given the data generated in earlier Phase II clinical studies of tabalumab," said Eiry Roberts, M.D., vice president of autoimmune product development at Lilly. "We remain committed to patients with rheumatoid arthritis and lupus and will move rapidly to evaluate the impact of these data on the overall tabalumab clinical development program. Beyond tabalumab,
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lilly Provides Update on Next Steps for Solanezumab
2. Lilly to Expand Indianapolis Insulin Manufacturing Operations
3. Lilly Names Melissa Barnes Chief Ethics and Compliance Officer and Senior Vice President; Announces Retirement of Anne Nobles
4. Lilly Celebrates 18th Consecutive Year as One of Working Mothers 100 Best Companies
5. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
6. Lilly Announces Results From Lung Cancer Study
7. Lilly Announces Retirement of Robert Armitage, Names Michael Harrington Senior Vice President and General Counsel
8. Lilly Stops Phase III Development of Pomaglumetad Methionil For the Treatment of Schizophrenia Based on Efficacy Results
9. U.S. Court of Appeals Upholds Validity of Lillys Alimta Compound Patent
10. Lilly Revises 2012 Reported Guidance to Reflect Income from Early Payment of Amylin Obligations
11. Lilly Announces Study Results Regarding Postmenopausal Women with Back Pain Caused by Vertebral Fractures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... CLEVELAND , Jan. 14, 2014 NineSigma ... will hold its Innovation Leadership Summit , May ... in Cleveland Ohio . ... innovators and organizations committed to breakthrough achievements through open ...
(Date:1/14/2014)... New York , January 14, 2014 ... Closed System Transfer Devices (CSTD) for hazardous drugs, today announced ... for the fourth straight year.   ... for pharmacy technicians, pharmacists, nurses and other medical ...
(Date:1/14/2014)... Spark Therapeutics , a late-stage gene therapy company, has ... a Phase 3 study for inherited retinal dystrophies caused by mutations ... Marrazzo , is presenting this and other corporate updates today, at ... Francisco . Marrazzo said Spark was able to achieve its ...
Breaking Medicine Technology:Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Equashield's Sales Grow by 60% in 2013 2Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness 2Spark Therapeutics Achieves Recruitment Goal in Phase 3 Gene Therapy Clinical Study for Inherited Blindness 3
... Bacterin International Holdings, Inc. (NYSE Amex: ... of revolutionary bone graft material and antimicrobial coatings for ... American Medical Concepts (AMC), the largest multi-specialty Orthopedic, Spine ... the U.S. The award gives Bacterin ,pre-approved, ...
... Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) ... (FDA) has scheduled a meeting of the Psychopharmacologic Drugs ... the ADASUVE New Drug Application (NDA) will be discussed. ... had accepted the resubmission of the ADASUVE NDA and ...
Cached Medicine Technology:Bacterin Awarded Approved Vendor Status for American Medical Concepts' Network of Hospitals in the Northwest U.S. 2Alexza Announces the Adasuve™ (Staccato® Loxapine) PDAC Meeting Date of December 12, 2011 2Alexza Announces the Adasuve™ (Staccato® Loxapine) PDAC Meeting Date of December 12, 2011 3
(Date:4/24/2014)... Nancy Chiaravalloti, PhD, of Kessler Foundation was named ... Jersey City, New Jersey. Dr. Chiaravalloti spoke on April ... the topic of "Treating Cognitive Deficits Following Neurological Illness ... be a part of the long legacy of the ... Chiaravalloti. "The field of rehabilitation research is a rewarding ...
(Date:4/24/2014)... scientists a better understanding of drug interactions, which are ... , When two or more medications are taken at ... effectiveness of the other. Similarly, one drug may ... are a major cause of illness and hospitalization. ... scope of drug studies in humans. Limits come ...
(Date:4/24/2014)... N.C. April 24, 2014 ,Take me out ... apple slices and kale chips. The more likely culprits ... Crackerjacks. , Unfortunately for children who play youth ... be contributing to weight problems, according to researchers at ... the current online edition of Childhood Obesity , ...
(Date:4/24/2014)... boring and irrelevant, could offer an alternative to heart ... Milena Furtado, and her team from the Australian Regenerative ... cell fibroblast is a close relative to a cardiomyocyte, ... In research published today in Circulation Research , ... cells due to their genetic program, and will aid ...
(Date:4/24/2014)... give than to receive at least if you,re an ... The study found that 15- and 16-year-olds who find pleasure ... members, are less likely to become depressed than those who ... money for themselves. , The researchers detail their findings in ... , The study focused on the ventral striatum, a brain ...
Breaking Medicine News(10 mins):Health News:Kessler Foundation scientist named 63rd Mendel Lecturer by St. Peter's University 2Health News:Large-scale identification and analysis of suppressive drug interactions 2Health News:Take the bat, leave the candy 2Health News:Boring cells could hold the key to heart disease 2Health News:Study: Altruistic adolescents less likely to become depressed 2
... doing the rounds that global warming in the East ... A novel research by an international team places ... malaria’s spread, along with other factors like drug and ... University of Michigan theoretical ecologist Mercedes Pascual, has contributed ...
... with danger, is also the color of blood, signaling perpetuation ... of blood on a daily basis to cater to patients ... Sunderland have set the ball rolling, campaigning and urging people ... the run-up to Easter. ,Take the case of ...
... suggests that patients on the newer medications for diabetics ... spent between $920 and $1,760 less on annual total ... lead author and the Merrell Dow professor of pharmacy ... of medical records data on patients who took thiazolidinediones ...
... between widely used childhood medicines and the risk of developing ... allergies, expose the kids to pets and dirt early. The ... is known as the hygiene hypothesis. , It ... fields and farm animals, leaves people more susceptible to a ...
... review of several studies conducted on cancer-causing chemicals has ... babies as a consequence of exposure to organochlorines//. Pesticides ... such chemicals and may be passed on to humans ... it can be indirectly passed on to human beings ...
... cancer is one of the deadliest diseases in UK. Symptoms ... a need to rush to the loo//. ,Hence ... to increase awareness about prostate cancer. Prostate cancer kills 220 ... UK. ,Mr Campbell has won the support ...
Cached Medicine News:Health News:New Diabetic Drugs More Effective than Older Ones 2Health News:A Sneak Preview of Human’s Susceptibility to Auto Immune Disease, Allergy, Asthm 2Health News:Parents Concerned About Pesticide And Cancer Risk To Babies 2
... Geometric Data Hemastainer. Formulated to ... quality control tested on human ... staining and absence of precipitate. ... a minimum of eight hours ...
... Unique molecular suspension in methanol ... blood, chromosome, and histology smears. Our ... that rapidly penetrates cellular elements producing ... nuclear detail and unexcelled brilliance in ...
Wright-Giemsa Stain Solutions...
... Stain is ideal for stat, routine or ... smears and bone marrow. Our unique manufacturing ... yield excellent color intensity and morphological differentiation. ... in the Wright's staining procedure and includes ...
Medicine Products: